Cancer Therapy Researchers Uncover Cancer Cell-killer
04 November 2024
A team from the Broad Institute of MIT and Harvard in collaboration from Industry leaders Bayer and Trueline Therapeutics, have developed a 'small molecule drug' labeled BRD-810. BRD-810 inhibits a protein called MCL1, which blocks apoptosis, or programmed cell death- a natural process- within many types of cancer cells.
Over 10-years of research at the Broad Institute have contributed to the development of BRD-810. Online news service MedicalXpress reports that "...BRD-810 that holds promise as a therapeutic candidate for cancer. This small molecule reactivates the apoptosis cascade in tumor cells while sparing healthy cells in animal models."*
The compound is eliminated from animal models bodies in about 4-hours, thus causing few, if any harmful side effects, according to the reports.
